Effect of Interleukin-6 Inhibitor (Tocilizumab) in Treatment of Severe Cases of COVID-19 in Intensive Care Unit, Prospective Clinical Trial

Background COVID-19 is a respiratory disease induced by a novel coronavirus (SARS- CoV-2), having already caused more than 2.5 million deaths over the world. Most people with COVID-19 have only mild or uncomplicated symptoms. Aim of the Work to study the effect of using Tocilizumab in treatment of severe cases of COVID-19 in ICU. Patients and Methods is a clinical trial study (Analytic, Intervention study, single arm, prospective); this study was carried out at Ain shams university hospitals. Results The mean Time to death from receiving Tocilizumab was 6.1888 ± 0.6 SD (Days), the mean Hospital length of stay 14.94 ± 1.85 SD (Days), the number of patients required Mechanical Ventilation was 29 Patients, the mean Duration of mechanical ventilation was 15.19 ± 1.094SD (Days), the number of patients who demonstrated clinical improvement was 38 (73%) and the number of patients who discharged alive was 31 (60%). Conclusion in critically ill adult patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists, Tocilizumab improved outcomes, including survival. Many patients achieved clinical improvement and were eventually discharged from the hospital.